Supplementary cash flow information

12 Months Ended

Dec. 31, 2017

Supplementary Cash Flow Information [Abstract]

Supplementary cash flow information

Supplementary cash flow information

Net change in other operating assets and liabilities

	2017 $		2016 $
Accounts receivable	(23	)	(39	)
Prepaid expenses and deposits	2		(949	)
Clinical trial contract deposits	(448	)	—
Accounts payable and accrued liabilities	2,168		2,458
	1,699		1,470
Interest received	973		34

Cash flows from financing and investing activities:

	Short term investments		Contingent consideration		Derivative warrants December 28, 2016		Derivative warrants February 14, 2014		Common shares		Warrants		Contributed surplus
Balance at January 1, 2017	—		(5,440	)	(7,405	)	(1,733	)	(299,815	)	(971	)	(17,017	)
Cash flow - Purchases	97,996		—		—		—		—		—		—
Cash flow - Disposals	(90,018	)	—		—		—		—		—		—
Cash flow - Payments made	—		2,150		—		—		—		—		—
Cash flow - Net proceeds from public offering	—		—		—		—		(162,324	)	—		—
Cash flow - Proceeds from exercise derivative warrants	—		—		8,596		88		(8,684	)	—		—
Cash flow - Proceeds from exercise warrants	—		—		—		—		(232	)	—		—
Cash flow - Proceeds from exercise options	—		—		—		—		(3,912	)	—		—
Non-cash changes - Conversion to Common Shares	—		—		3,825		8,760		(21,334	)	65		2,899
Non-cash changes - Fair value adjustments	(78	)	(502	)	(17,808	)	(10,973	)	(2,899	)	—		—
Non-cash changes - Stock Based Compensation	—		—		—		—		—		—		(4,242	)
Non-cash changes - Other	(67	)	—		3,844		1,013		—		—		—
Balance at December 31, 2017	7,833		(3,792	)	(8,948	)	(2,845	)	(499,200	)	(906	)	(18,360	)